Pharmaceutical company Amgen has reacquired the remaining rights to three medications from GSK.
The medications include Prolia (denosumab), which is used to treat osteoporosis in post-menopausal women; Xgeva (denosumab), which is indicated for the treatment of patients with bone metastases from solid tumors; and Vectibix (panitumumab), which is used in the treatment of metastatic colorectal cancer (mCRC).
GSK generated about $111 million from the sales of these therapies in 2014.
"This unique agreement with GSK allows Amgen to regain rights to three important growth products and to directly serve more patients in key expansion markets," Robert Bradway, chairman and CEO of Amgen, said. "The agreement also allows Amgen to build additional commercial infrastructure in oncology and bone health, two strategically important therapeutic areas for Amgen with emerging late-stage pipeline assets."
Prolia is administered by injection once every six months and works by regulating bone-removing cells. It is also prescribed to osteoporotic men to increase bond mass. Xgeva is administered by injection every four weeks. It was approved in 2013 and is the only FDA-approved treatment for adults with giant cell tumors of the bones. Vectibix was approved in 2006 and is administered via intravenous infusion.
